This company is a clinical - stage biopharmaceutical company engaged in developing novel therapies to address disabling neuropsychiatric conditions characterized_by significant unmet_medical need. It conducts_business_from its_registered_head office_located in CITY, COUNTRY COUNTRY COUNTRY COUNTRY. The company was_established in DATE. The company develops muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment including schizophrenia and CAUSE_OF_DEATH_CAUSE_OF_DEATH_CAUSE_OF_DEATH, and neuropathic pain. Its pipeline is built_on the broad therapeutic potential of its lead product TITLE, KarXT, an oral modulator of muscarinic receptors that are located both in the central_nervous_system, or ORGANIZATION, and various peripheral tissues. KarXT is ita proprietary product TITLE that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS.The company 's purpose is to_create and deliver transformative medicines for people living with psychiatric and neurological conditions.